Molecular Therapeutics

Type: Company
Name: Molecular Therapeutics
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

De novo activation of MYC by CRTC1/MAML2 [Biochemistry]

Antonio L. Amelio a , 1 , Mohammad Fallahi b , Franz X. Schaub a , Min Zhang c , Mariam B. Lawani a , Adam S. Alperstein a , Mark R. Southern d , Brandon M. Young e , Lizi Wu f , Maria Zajac-Kaye c , g , Frederic J. Kaye c , John L. Cleveland ... [Published PNAS - Jul 29 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center

OncLive® is pleased to announce that UNC Lineberger Comprehensive Cancer Center has joined its Strategic Alliance Partnership program.By participating in the Strategic Alliance Partnership program, UNC Lineberger will have the opportunity to work with ... [Published Bio-Medicine - Jul 23 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Report Summarizes Molecular Therapeutics Study Findings from University of Rochester School of Medicine and Dentistry (Nanoparticle-mediated gene...

at 17:47 PM EDT Report Summarizes Molecular Therapeutics Study Findings from University of Rochester School of Medicine and Dentistry (Nanoparticle-mediated gene silencing confers radioprotection to salivary glands in vivo) By a News Reporter-Staff News ... [Published Industrial Info Financials - Jul 09 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Recent Developments in Novel Antidepressants Targeting α4β2-Nicotinic Acetylcholine Receptors

† Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, United States‡ NeuroBehavior Laboratory, Harvard NeuroDiscovery Center and Department of Neurology, Brigham and Women’s ... [Published Journal of Medicinal Chemistry - Jul 03 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Researchers from University of Toronto Report on Findings in Drug Delivery Systems (Imaging the Cytosolic Drug Delivery Mechanism of HDL-Like...

Researchers from University of Toronto Report on Findings in Drug Delivery Systems (Imaging the Cytosolic Drug Delivery Mechanism of HDL-Like Nanoparticles)By a News Reporter-Staff News Editor at Biotech Week A new study on Drugs and Therapies is now ... [Published Pharmacy Choice - Jul 02 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Renewed hope for gene therapy in rare disease

Between 30 and 40 million people in Europe suffer from rare diseases—many of them children. As most of these diseases have genetic origins, gene therapy is a major hope for their future cure. Until now, however, there have been very few successful trials. ... [Published Medical Xpress - Jul 02 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Award Winners at the Seventh Edition of the Martín Villar Research Awards

The publication "Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys" by Mingozzi F, Anguela XM, Pavani G, Chen Y, Davidson RJ, Hui DJ, Yazicioglu M, Elkouby L, Hinderer CJ, Faella A, Howard C, Tai A, Podsakoff GM, Zhou S, Basner-Tschakarjan ... [Published Noodls - Jul 01 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 2 reports

Data on Molecular Therapeutics Described by Researchers at University of Iowa (Multifunctional Aptamer-miRNA Conjugates for Targeted Cancer Therapy)

at 22:44 PM EDT By a News Reporter-Staff News Editor at Biotech Week -- A new study on Biotechnology is now available. According to news reporting out of Iowa City, Iowa, by NewsRx editors, research stated, "While microRNAs ... ... [Published Industrial Info Financials - Jun 26 2014]
First reported Apr 21 2014 - Updated Apr 22 2014 - 1 reports

HERS Breast Cancer Foundation Event Honors Community Leadership in...

The fifth annual People with Purpose Awards Luncheon on April 24 recognizes the contributions of local nonprofits, business leaders, and doctors in support of breast cancer survivors. HERS Breast Cancer Foundation today announced that they are hosting ... [Published PRWeb - Apr 21 2014]
First reported Feb 13 2014 - Updated Feb 13 2014 - 1 reports

Forbion Capital-backed uniQure completes IPO

Forbion Capital Partners -backed uniQure , which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ . Jefferies and Leerink Partners acted as joint book-running managers and Piper ... [Published PE Hub Blog - Feb 13 2014]

Quotes

According to the news editors, the research concluded: "This cytosolic delivery strategy can be utilized for transporting molecular therapeutics that require their action sites to be within cytosolic organelles to enhance therapeutic effect."
One additional problem is that "once the virus has reached its target, in some organs there seems to be a cellular response. And the cells that were successfully treated are destroyed" Basner-Tschakarjan tells youris.com, concluding: "Therefore, the positive effect at the beginning goes away."
...The publication "Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter" by Repesse Y, Peyron I, Dimitrov JD, Dasgupta S, Farrokhi Moshai E, Costa C, Borel-Derlon A, Guillet B, D'Oiron R, Aouba A, Rothschild C, Oldenburg J...
...According to news reporting out of Iowa City, Iowa , by NewsRx editors, research stated, "While microRNAs (miRNAs) clearly regulate multiple pathways integral to disease development and progression, the lack of safe and reliable means for specific delivery of miRNAs to target tissues represents a major obstacle to their broad therapeutic application. Our objective was to explore the use of nucleic acid aptamers as carriers for cell-targeted delivery of a miRNA with tumor suppressor function, let-7g."

More Content

All (12) | News (10) | Reports (0) | Blogs (1) | Audio/Video (1) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
De novo activation of MYC by CRTC1/MAML2 [Bioch... [Published PNAS - Jul 29 2014]
OncLive Expands Its Strategic Alliance Partners... [Published Bio-Medicine - Jul 23 2014]
Report Summarizes Molecular Therapeutics Study ... [Published Industrial Info Financials - Jul 09 2014]
Recent Developments in Novel Antidepressants T... [Published Journal of Medicinal Chemistry - Jul 03 2014]
Researchers from University of Toronto Report o... [Published Pharmacy Choice - Jul 02 2014]
Renewed hope for gene therapy in rare disease [Published Medical Xpress - Jul 02 2014]
Award Winners at the Seventh Edition of the Mar... [Published Noodls - Jul 01 2014]
Data on Molecular Therapeutics Described by Res... [Published Industrial Info Financials - Jun 26 2014]
Data on Molecular Therapeutics Described by Res... [Published HispanicBusiness.com - Jun 26 2014]
HERS Breast Cancer Foundation Event Honors Comm... [Published PRWeb - Apr 21 2014]
The Humor Code [Published Slate Magazine - Mar 27 2014]
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
Forbion Capital Partners -backed uniQure , which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ . Jefferies and Leerink Partners acted as joint book-running managers and Piper ...
1

Audio/Video

sort by: Date | Relevance
The Humor Code [Published Slate Magazine - Mar 27 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.